Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceIbrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaThe influence of subclonal resistance mutations on targeted cancer therapyNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsMyeloid Cells as Targets for Therapy in Solid TumorsThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesClinical implications of the molecular genetics of chronic lymphocytic leukemiaBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibManagement of mantle cell lymphoma in the elderly patientB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292How will B-cell-receptor-targeted therapies change future CLL therapy?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewIn situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12CThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.Integrative systems medicine approaches to identify molecular targets in lymphoid malignanciesThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSecond-generation inhibitors of Bruton tyrosine kinaseManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentTargets for Ibrutinib Beyond B Cell MalignanciesTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaPI3K and cancer: lessons, challenges and opportunitiesDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaHigh-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
P2860
Q26738946-5E5A0271-69B3-4F3D-B46A-0ABF52ABF7E0Q26749010-91DBDB67-6FFE-4D9F-AD02-79A9D2EB0F32Q26749139-E386B23A-1C56-43EC-8F05-36A8FA1BC66AQ26775506-78DE5B0E-D45A-4B10-8EDB-96CC031B1BA7Q26781693-10D1494D-9190-4B12-A326-67B6D06DDC37Q26782270-F43D68EA-FC96-4E4A-A44A-078A99EAD15BQ26783430-E79B7A0A-A4FE-4C97-B44A-EDCB8439F37CQ26795594-BBEFD843-953D-420E-9A5E-7B060B98325FQ26801832-EC90884F-C757-4244-8FF5-5E40AB2CE7E8Q26822700-19793B94-9ED5-451C-9C82-1144920C5EE1Q26828782-D7BBD6DF-D0B9-4C21-972F-E65895BD323EQ26830955-67958898-86CB-42ED-B523-012DB90C7861Q26991890-BBDAA39D-FC27-4C4D-B624-4C69A2CAE80AQ26995113-764D30AC-7781-4FE6-825D-3C3BC0A2164AQ26999395-4CFC65F4-1751-4D4D-9FB0-74B1DF6D10C8Q27009550-EE6C85D5-89C3-4C55-9BC0-4C41E98252C7Q27024187-C428CC32-B279-4377-BE08-9D6A2A6E90CAQ27025812-4590CDA8-9CBF-4C6C-B864-23A4ECD85313Q27026912-6712F9BB-AA83-473C-9C39-486B8D998A79Q27304386-F5A08165-BF40-4874-9727-167AAE44520DQ27684047-AF0E330B-1B56-4842-A504-A13CF15C4B7AQ27687567-3C1B437E-AF0D-4421-A7A2-41CFEC699B14Q28067817-3ACA5E58-0C2D-4B9E-9962-4D6C6CA7A169Q28072397-B10BC795-7AA8-4A10-900A-F9FAB09FDCC4Q28075504-6F53A635-8B31-4AAF-A41C-25CFE80B3AA2Q28076118-373CBFF3-42F3-4686-AAFC-62CEB7060E32Q28081162-77050AA1-28F2-4DE8-9B24-8641042F5990Q28082086-8D92993E-F601-46AD-B5F7-FC355F83111AQ28087772-EFF3F4D0-18CC-4B91-8CDA-AC0C18F68E9BQ29620690-BEA446A4-E8D7-4FD4-8BD6-843474197DF5Q30080017-975D8BB1-AA55-4AB7-9562-A4E2724B7600Q30235296-457E98A6-E37C-430E-B5EE-42790A61A491Q30252869-571500C2-92D3-43CF-9B50-43D57B70B0DAQ30303054-D83AA6A4-2313-47F4-8C75-880E03A319CBQ30371806-2A7475F1-713D-4790-98B7-448912D6E4BCQ30433183-C80918AA-2B23-4C78-A470-F21CA98BA4D5Q30456436-AF9A3D52-661B-475F-ABD7-351509760622Q33412064-58D19486-CEA5-4B9A-9BA4-98CAE654D24EQ33413834-51EC9A08-5894-449E-B787-F59C55F54001Q33419003-C5D5E7FC-5892-48CF-8E86-D9D51828A19E
P2860
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@ast
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@en
type
label
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@ast
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@en
prefLabel
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@ast
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@en
P2093
P2860
P356
P1476
Bruton tyrosine kinase inhibit ...... efractory B-cell malignancies.
@en
P2093
Ahmed Hamdy
Barbara Grant
Betty Y Chang
Eric Hedrick
Jeff P Sharman
Joseph J Buggy
Juthamas Sukbuntherng
Kathryn S Kolibaba
Nathan H Fowler
Ranjana H Advani
P2860
P356
10.1200/JCO.2012.42.7906
P407
P577
2012-10-08T00:00:00Z